129 related articles for article (PubMed ID: 34584129)
1. Liraglutide Treatment in a Morbidly Obese Adolescent with a
Çamtosun E; Akıncı A; Kayaş L; Çiftçi N; Tekedereli İ
J Clin Res Pediatr Endocrinol; 2023 May; 15(2):225-229. PubMed ID: 34584129
[TBL] [Abstract][Full Text] [Related]
2. Patients with Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated with a Glucagon-like Peptide-1 Receptor Agonist.
Iepsen EW; Zhang J; Thomsen HS; Hansen EL; Hollensted M; Madsbad S; Hansen T; Holst JJ; Holm JC; Torekov SS
Cell Metab; 2018 Jul; 28(1):23-32.e3. PubMed ID: 29861388
[TBL] [Abstract][Full Text] [Related]
3. GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report.
Iepsen EW; Have CT; Veedfald S; Madsbad S; Holst JJ; Grarup N; Pedersen O; Brandslund I; Holm JC; Hansen T; Torekov SS
Cell Rep Med; 2020 Apr; 1(1):100006. PubMed ID: 33205056
[TBL] [Abstract][Full Text] [Related]
4. Semaglutide, A Long-Acting GLP-1 Analogue, for the Management of Early Onset Obesity due to MC4R defect - A Case Report.
Gokul PR; Apperley L; Parkinson J; Clark K; Lund K; Owens M; Senniappan S
Horm Res Paediatr; 2024 Feb; ():. PubMed ID: 38402868
[TBL] [Abstract][Full Text] [Related]
5. Dual melanocortin-4 receptor and GLP-1 receptor agonism amplifies metabolic benefits in diet-induced obese mice.
Clemmensen C; Finan B; Fischer K; Tom RZ; Legutko B; Sehrer L; Heine D; Grassl N; Meyer CW; Henderson B; Hofmann SM; Tschöp MH; Van der Ploeg LH; Müller TD
EMBO Mol Med; 2015 Mar; 7(3):288-98. PubMed ID: 25652173
[TBL] [Abstract][Full Text] [Related]
6. Melanocortin 4 receptor (MC4R) gene variants in children and adolescents having familial early-onset obesity: genetic and clinical characteristics.
Aykut A; Özen S; Gökşen D; Ata A; Onay H; Atik T; Darcan Ş; Özkinay F
Eur J Pediatr; 2020 Sep; 179(9):1445-1452. PubMed ID: 32185475
[TBL] [Abstract][Full Text] [Related]
7. Adults with pathogenic MC4R mutations have increased final height and thereby increased bone mass.
Iepsen EW; Zhang J; Hollensted M; Madsbad S; Hansen T; Holst JJ; Jørgensen NR; Holm JC; Torekov SS
J Bone Miner Metab; 2020 Jan; 38(1):117-125. PubMed ID: 31471646
[TBL] [Abstract][Full Text] [Related]
8. Weight and Glycemic Control Outcomes of Bariatric Surgery and Pharmacotherapy in Patients With Melanocortin-4 Receptor Deficiency.
Fojas EGF; Radha SK; Ali T; Nadler EP; Lessan N
Front Endocrinol (Lausanne); 2021; 12():792354. PubMed ID: 35095762
[TBL] [Abstract][Full Text] [Related]
9. GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women.
Iepsen EW; Lundgren JR; Hartmann B; Pedersen O; Hansen T; Jørgensen NR; Jensen JE; Holst JJ; Madsbad S; Torekov SS
J Clin Endocrinol Metab; 2015 Aug; 100(8):2909-17. PubMed ID: 26043228
[TBL] [Abstract][Full Text] [Related]
10. Successful naltrexone-bupropion treatment after several treatment failures in a patient with severe monogenic obesity.
Welling MS; Mohseni M; van der Valk ES; van Hagen JM; Burgerhart JS; van Haelst MM; van Rossum EFC
iScience; 2023 Mar; 26(3):106199. PubMed ID: 36876127
[TBL] [Abstract][Full Text] [Related]
11. Chronic intrahypothalamic rather than subcutaneous liraglutide treatment reduces body weight gain and stimulates the melanocortin receptor system.
Kaineder K; Birngruber T; Rauter G; Obermüller B; Eichler J; Münzker J; Al-Zoughbi W; Mautner SI; Torekov SS; Hartmann B; Kotzbeck P; Pieber TR
Int J Obes (Lond); 2017 Aug; 41(8):1263-1270. PubMed ID: 28507313
[TBL] [Abstract][Full Text] [Related]
12. Melanocortin 4 receptor mutations in obese Czech children: studies of prevalence, phenotype development, weight reduction response, and functional analysis.
Hainerová I; Larsen LH; Holst B; Finková M; Hainer V; Lebl J; Hansen T; Pedersen O
J Clin Endocrinol Metab; 2007 Sep; 92(9):3689-96. PubMed ID: 17579204
[TBL] [Abstract][Full Text] [Related]
13. Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults.
Lean ME; Carraro R; Finer N; Hartvig H; Lindegaard ML; Rössner S; Van Gaal L; Astrup A;
Int J Obes (Lond); 2014 May; 38(5):689-97. PubMed ID: 23942319
[TBL] [Abstract][Full Text] [Related]
14. Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Jensterle Sever M; Kocjan T; Pfeifer M; Kravos NA; Janez A
Eur J Endocrinol; 2014 Mar; 170(3):451-9. PubMed ID: 24362411
[TBL] [Abstract][Full Text] [Related]
15. Off-label antiobesity treatment in patients without diabetes with GLP-1 agonists in clinical practice.
Sauer N; Reining F; Schulze Zur Wiesch C; Burkhardt T; Aberle J
Horm Metab Res; 2015 Jul; 47(8):560-4. PubMed ID: 25230325
[TBL] [Abstract][Full Text] [Related]
16. Familial early-onset obesity in Turkish children: variants and polymorphisms in the melanocortin-4 receptor (MC4R) gene.
Kırmızıbekmez H; Kendir Demirkol Y; Akgün Doğan Ö; Seymen G; İnan Balcı E; Atla P; Dursun F
J Pediatr Endocrinol Metab; 2022 May; 35(5):657-662. PubMed ID: 35355494
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-like peptide-1 receptor agonists for weight loss in adult patients without diabetes.
Ottney A
Am J Health Syst Pharm; 2013 Dec; 70(23):2097-103. PubMed ID: 24249759
[TBL] [Abstract][Full Text] [Related]
18. Effect of the glucagon-like peptide-1 analogue liraglutide versus placebo treatment on circulating proglucagon-derived peptides that mediate improvements in body weight, insulin secretion and action: A randomized controlled trial.
Kim SH; Abbasi F; Nachmanoff C; Stefanakis K; Kumar A; Kalra B; Savjani G; Mantzoros CS
Diabetes Obes Metab; 2021 Feb; 23(2):489-498. PubMed ID: 33140542
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of weight loss and metabolic changes in diabetic patients treated with liraglutide, effect of RS 6923761 gene variant of glucagon-like peptide 1 receptor.
de Luis DA; Diaz Soto G; Izaola O; Romero E
J Diabetes Complications; 2015; 29(4):595-8. PubMed ID: 25825013
[TBL] [Abstract][Full Text] [Related]
20. FTO and MC4R gene variants determine BMI changes in children after intensive lifestyle intervention.
Zlatohlavek L; Vrablik M; Motykova E; Ceska R; Vasickova L; Dlouha D; Hubacek JA
Clin Biochem; 2013 Mar; 46(4-5):313-6. PubMed ID: 23201545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
